WASHINGTON — President Trump told pharmaceutical companies last week that they should start building infrastructure in the U.S. — or face a 100% tariff, starting Wednesday.
But a White House official told STAT on Wednesday that the tariffs have not gone into effect and that the administration would now “begin preparing” tariffs on companies that don’t build in the U.S. or make a drug pricing agreement with the administration. The official didn’t share a new timeline for those import taxes, which would apply to branded drugs.
The postponement signals that months of tough talk from the White House on pharma tariffs may ultimately be aimed at leveraging more voluntary commitments from drugmakers, such as investing in the U.S. and striking deals to lower their prices.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
Source link
